Article Details
Retrieved on: 2025-04-26 05:06:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Zymeworks Inc.'s development of biopharmaceutical therapies focusing on cancer immunotherapy. This includes antibody-drug conjugates and T cell engagers, demonstrating advancements in targeting molecules like PTK7 and HER2, aligning with tags such as 'Antibody', 'Immunology', and companies like 'Sutro Biopharma' and 'ZYMEWORKS INC'.
Article found on: www.finanzen.ch
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here